Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Carnosine synthesis pathway" is not itself a single molecular target but refers to the **biosynthetic process** that produces the dipeptide carnosine from its constituent amino acids, β-alanine and L-histidine[3][4]. The key enzyme responsible for this reaction is **carnosine synthase** (CARNS1), which catalyzes the ATP-dependent condensation of β-alanine and L-histidine to form carnosine[1][2][4]. This enzyme belongs to the ligase class (EC 6.3.2.11) and is sometimes referred to as "carnosine synthetase"[5]. Carnosine itself plays important roles in muscle tissue as a pH buffer, antioxidant, metal chelator, regulator of calcium ions and enzymes, and inhibitor of protein glycosylation[5][6]. The pathway also includes related enzymes such as **carnosinase** (for degradation) and **carnosine N-methyltransferase** for methylated analogs like anserine[1][4]. Because "Carnosine synthesis pathway" describes a metabolic process rather than a discrete molecular entity or druggable target such as an enzyme or receptor, it should not be considered a canonical therapeutic target on its own—rather, its key component enzyme (**carnosine synthase/CARNS1**) is the relevant molecular target. Therefore: - The correct canonical name for targeting purposes would be "**Carnosine synthase**". - The abbreviation is "**CARNS1**". - It is an **enzyme**, specifically a ligase. - If you are seeking structured information about drug targets or biomarkers related to this pathway/process rather than individual molecules/enzymes within it ("pathway" vs "target"), then this entry should be marked as incorrect (`is_incorrect: true`) because pathways are not direct therapeutic targets; their constituent enzymes/proteins are. If you need information on specific drugs or inhibitors/modulators acting on CARNS1/carnosinases or other components in this pathway, there currently appear to be no approved drugs directly targeting these enzymes in clinical use[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carnosine synthase (CARNS1).